Loading
Three years of imatinib after surgery for high-risk gastrointestinal stromal tumour reduced recurrences and deaths compared with one year, setting the standard duration of adjuvant therapy.
Phase 3 trial of 400 patients with resected KIT-positive GIST at high risk of recurrence randomised to 12 or 36 months of adjuvant imatinib 400 mg daily.
Five-year recurrence-free survival was 65.6 versus 47.9 percent (hazard ratio 0.46) and five-year overall survival 92.0 versus 81.7 percent (hazard ratio 0.45); ten-year follow-up confirmed the survival benefit, and discontinuation for adverse events was more common with longer treatment.
Three years of adjuvant imatinib is standard for high-risk resected GIST with imatinib-sensitive mutations; longer courses are being tested.
Shares KIT exon 11-mutant GIST, Imatinib.
Shares KIT exon 11-mutant GIST, Imatinib.
Shares KIT exon 11-mutant GIST, Imatinib.
Shares KIT exon 11-mutant GIST, Imatinib.
Shares KIT exon 11-mutant GIST, Imatinib.
Shares Heikki Joensuu, KIT exon 11-mutant GIST, Imatinib.